These independent CME/CE activities are supported by educational grants from Bristol-Myers Squibb

Genentech BioOncology

Novartis Pharmaceuticals Corporation
The Advanced Certificate Program in
Breast Cancer Management
  1. Curriculum III
  2. Curriculum II
  3. Curriculum I
  4. Full Course List
Chair
faculty image
Harold J. Burstein, MD, PhD
  • Associate Professor of Medicine
  • Dana-Farber Cancer Institute
  • Harvard Medical School
  • Boston, Massachusetts
    • Projects In Knowledge is pleased to present The Advanced Certificate Program: Breast Cancer Management.

    Featuring the very latest state-of-the-science information about breast cancer diagnosis, breast cancer treatment, and breast cancer disease management, this free online curriculum offers CME, CE, and CPE credit to oncologists and other clinicians who care for patients with breast cancer.

    The curriculum courses are updated continuously throughout the year.

    The Advanced Certificate Program: Breast Cancer Management is building a community of experts to help you provide your patients with the best treatment outcome possible.
  • Assess risk factors, genetics, and biologic subsets as predictors of response to determine which breast cancer patients are likely to benefit from specific therapies to improve their outcomes.
  • Apply evidence-based guidelines to formulate treatment strategies for patients with early- and late-stage breast cancer.
  • Utilizing knowledge of their efficacy and safety, evaluate the appropriate use of chemotherapeutic and targeted agents in treatment strategies that improve outcomes in breast cancer patients.
  • Integrate targeted and novel therapies into more successful treatment regimens for breast cancer patients by assessing the efficacy and safety of these agents.
    • Early stage breast cancer management
      • Chemotherapy
      • Endocrine/hormone therapy
      • Targeted therapy
    • Metastatic breast cancer management
      • Chemotherapy
      • Hormone therapy
      • Targeted therapies
        - Anti-HER2 agents
        - Antiangiogenic agents
      • Bone metastasis management
    • Neoadjuvant therapy
      • Translational therapy
    • Hereditary breast cancer
    • Adjuvant treatment for premenopausal women
    • Hormone-receptor-positive breast cancer
    • Primary endocrine therapy
    • Estrogen-receptor-positive breast cancer
    • Third line chemotherapy in metastatic breast cancer
    • Biomolecular predictors
    • Adjuvant systemic therapy in early stage breast cancer
    • Estrogen-responsive genes in metastases to the bone
    • Cancer risk assessment with biomarkers
    • Postoperative treatment with targeted therapies for patients with HER2+ & HER2-
    • Dose-dense adjuvant therapy
    • Hormonal therapy for advanced breast cancer
    • Neoadjuvant systemic therapy
    • Molecular screening for breast cancer
    • 21-gene recurrence score prognostic assay

    Target Audience

    This series of activities is designed for oncologists and other clinicians who specialize in and care for patients with breast cancer.

     

    Activity Goal

    The goal of these CME/CE activities is to examine current and emerging strategies for treating and managing patients with breast cancer.